Oral Cyclophosphamide and Etoposide in Treatment of Malignant Pleural Mesothelioma


Background: Malignant mesothelioma (MM) is almost always fatal and few treatment options are available.The aim of this study was to evaluate the efficacy of oral cyclophosphamide and etoposide for patients whounderwent standard treatment for advanced MM. Materials and
Methods: This study included 22 malignantpleural mesothelioma patients who were treated with oral cyclophosphamide and etoposide (EE).
Results: Theaverage follow-up period of the patients was 39.1 months. Under the treatment of oral EE, median progressionfreesurvival was 7.7 months [95%CI HR (4.3-11.1)] and median overall survival was 28.1 months [95%CI HR(5.8-50.3)]. The treatment response rates were as follows: 4 patients (27.3%) had a partial response (PR), 12(54.5%) had stable disease (SD), and progressive disease (PD) was observed in 6 (35.9%).
Conclusions: OralEE can be administered effectively to patients with inoperable malignant mesothelioma who had previouslyreceived standard treatments.